Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04155411 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | unknown | Phase 4 | 65 | Shenzhen Second People's HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02389920 | Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib | unknown | Phase 4 | 40 | Samsung Medical CenterOTHER | 0 | Mar 17, 2015 | clinicaltrials |
| NCT02317159 | Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia | unknown | Phase 4 | 90 | CttqINDUSTRY | 0 | Dec 15, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2022source: clinicaltrials